Elutia Inc. (ELUT)
| Market Cap | 41.60M -53.2% |
| Revenue (ttm) | 12.14M -45.0% |
| Net Income | 51.81M |
| EPS | 0.85 |
| Shares Out | 44.21M |
| PE Ratio | 1.11 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 71,124 |
| Open | 0.8799 |
| Previous Close | 0.8603 |
| Day's Range | 0.8600 - 0.9500 |
| 52-Week Range | 0.5000 - 2.5000 |
| Beta | 0.88 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About ELUT
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac pat... [Read more]
Financial Performance
Financial StatementsNews
Elutia Earnings Call Transcript: Q2 2026
Q2 saw focused execution with divestitures and $26M in new funding, supporting NXT-41x development and launch. Gross margin improved to 70.7% (adjusted), net loss narrowed, and surgeon demand for NXT-41x is strong. Regulatory and manufacturing milestones remain on track.
Elutia Earnings release: Q2 2026
Elutia released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Elutia Slides: Q2 2026
Elutia has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Elutia Quarterly report: Q2 2026
Elutia has published its Q2 2026 quarterly earnings report on August 13, 2026.
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
Funded through launch: secured up to $26 million of capital without an equity offering The unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection risk The dema...
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
$10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41x Preserves shareholder value by funding commercialization of Elutia's next-generation antibiotic-e...
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
GAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its ...
Elutia to sell SimpliDerm business to Cellution Biologics for $11M
Elutia (ELUT) announced the signing of a definitive agreement to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics for total consideration of up to $11M. Elutia will…
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
Elutia Transcript: Planet MicroCap Las Vegas 2026
A drug-eluting biologic platform is being advanced for breast reconstruction, addressing a $1.5 billion U.S. market with high infection rates. The product delivers local antibiotics via mesh, with regulatory approval expected next year and a focused commercialization plan targeting top centers.
Elutia to Present at Planet MicroCap Showcase 2026 on June 17th
GAITHERSBURG, Md., June 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chi...
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awa...
Elutia Transcript: 16th Annual LD Micro Invitational Conference
A proven antibiotic-eluting matrix platform is being adapted for breast reconstruction, targeting a $1.5 billion U.S. market with high infection rates. FDA approvals are expected within a year, with a cost-neutral, high-margin commercialization strategy focused on top hospitals.
Elutia Earnings Call Transcript: Q1 2026
Q1 2026 saw 6% revenue growth, improved gross margins, and strong liquidity. Regulatory progress and manufacturing advances support confidence in NXT-41x, with FDA clearance and commercialization targeted for 2026–2027. Strategic divestitures are underway.
Elutia Earnings release: Q1 2026
Elutia released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Elutia Slides: Q1 2026
Elutia has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
Elutia Quarterly report: Q1 2026
Elutia has published its Q1 2026 quarterly earnings report on May 14, 2026.
Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market
NXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparations Brought a new automated manufacturing process online, supporting a gross margin target of more than 80% at s...
Elutia to Present at the 16th Annual LD Micro Invitational on May 18th
GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chie...
Elutia to Present at the 16th Annual LD Micro Invitational May 18th
Gaithersburg, Maryland--(Newsfile Corp. - May 14, 2026) - Elutia Inc. (NASDAQ: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills...
Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its...
Elutia Proxy statement: Proxy filing
Elutia filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Elutia Proxy statement: Proxy filing
Elutia filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Elutia Transcript: Sidoti March Small-Cap Virtual Conference
A new drug-eluting biologic for breast reconstruction aims to address a $1.5B market with high infection rates by delivering antibiotics directly at the surgical site. FDA approval for the base matrix is expected this year, with the drug-eluting version targeted for next year.
Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
GAITHERSBURG, Md., March 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Ch...